Table 3 Main pharmacokinetic results in the thirteen patients under analysis

From: Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer

 

Cisplatin

Paclitaxel

Patient

Cmax plasma ( μ g ml−1)

Cmax perfusate ( μ g ml−1)

Cmax tissue ( μ g g−1)

C max perfusate/C max plasma

Cmax plasma ( μ g ml−1)

Cmax perfusate ( μ g ml−1)

Cmax tissue ( μ g g−1)

C max perfusate/C max plasma

1

1.50

22.41

NA

14.91

<LOQ

71.23

34.88

 

2

1.51

43.95

11.1

29.11

<LOQ

86.08

20.22

 

3

2.04

47.22

26.9

23.18

<LOQ

84.13

40.18

 

4

2.41

31.02

34.9

12.85

0.048

87.52

42.83

1823.33

5

1.42

28.32

NA

19.97

<LOQ

95.78

24.44

 

6

2.08

20.33

17.6

9.76

<LOQ

56.1

68.334

 

7

2.03

22.69

25.1

11.20

0.068

72.0

41.85

1056.85

8

1.90

20.49

28.8

10.80

<LOQ

64.6

15.774

 

9

1.83

20.23

NA

11.05

0.063

63.3

40.2

1004.68

10

2.32

20.22

NA

8.71

0.062

56.1

40.512

905.97

11

1.12

16.49

NA

14.72

0.044

61.2

5.41

1390.91

12

2.11

16.70

19.0

7.91

0.050

52.0

4.51

1040.00

13

2.02

12.66

NA

6.27

0.050

57.6

11.96

1152.00

Mean±s.d.

1.87±0.37

24.83±10.38

23.33±7.97

13.88±6.58

0.055±0.009

69.82±14.29

30.08±18.31

1196.25±315.67

  1. Abbreviations: LOQ=limit of quantification (0.050 μg ml−1); NA=tissue not available.
Back to article page